TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12105285
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 400 mg/d
Study: 31232139
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (40 mg/d) combined with aspirin (100 mg/d)
Study: 31232139
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose atorvastatin (20 mg/d) combined with aspirin (100 mg/d)
Study: 14574055
Drug: BNP-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided treatment
Study: 15671129
Drug: Oral zuclopenthixol
Normalized name: zuclopenthixol
DrugBank: Zuclopenthixol (DB01624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zuclopenthixol
Study: 11910616
Drug: Transdermal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal progesterone cream (16, 32, or 64 mg daily for 14 days)
Study: 11910616
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (continuous for 28-day cycle)
Study: 8116856
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (162 mg)
Study: 8116856
Drug: Furosemide (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (18 mg)
Study: 8116856
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lysine acetylsalicylate and furosemide
Study: 30445008
Drug: Dexlansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole (60 mg)
Study: 31764785
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/day, orally)
Study: 31764785
Drug: LMWH (Enoxaparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (Enoxaparin, 4000 anti-Xa IU/day, subcutaneous injection)
Study: 31764785
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anticoagulant)
Study: 28499376
Drug: Mindfulness-based childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based childbirth preparation course (MIL)
Study: 28499376
Drug: Standard childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard childbirth preparation course (Control)
Study: 12911658
Drug: Ecabet sodium
Normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecabet sodium 1 g b.i.d and cimetidine 400 mg b.i.d.
Study: 11164441
Drug: Therapeutic goal
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic goal of total cholesterol < 5.0 mmol/l
Study: 11164441
Drug: Therapeutic goal
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic goal of total cholesterol < 4.5 mmol/l
Study: 9280037
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran fibre supplement
Study: 8243794
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day tenoxicam
Study: 8243794
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day diclofenac sodium
Study: 29305240
Drug: RUSF+Arg/Citr (Arg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUSF+Arg/Citr (Arg, 0.2 g/kg/day; Citr, 0.1 g/kg/day) with daily chloroquine (50 mg)
Study: 17493066
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with latex extract
Study: 17239657
Drug: sumanirole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumanirole (all doses)
Study: 14971965
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g Cr + 18 g dextrose taken 4 times per day for 5 days
Study: 9389813
Drug: Cyproterone acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate, 12.5 mg, and T undecanoate, 80 mg, administered orally twice daily for 16 weeks
Study: 7697688
Drug: Enteric-coated (EC)
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated (EC) naproxen tablets 500 mg twice daily
Study: 2959197
Drug: Teicoplanin-rifampin combination
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin-rifampin combination
Study: 27302208
Drug: Monthly vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly vitamin D3 supplementation (40,000 IU/month)
Study: 17475412
Drug: Antiandrogenic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogenic oral contraceptive (30 microg ethinyl estradiol combined with 3 mg drospirenone) for 3 months
Study: 15675932
Drug: Caudal S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal S(+)‐ketamine 1 mg.kg(‐1) (group K)
Study: 15675932
Drug: Caudal S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal S(+)‐ketamine 0.5 mg.kg(‐1) plus neostigmine 10 microg.kg(‐1) (group KN)
Study: 10030482
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy services
Study: 7757308
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg t.i.d.)
Study: 6153847
Drug: L-lysine monohydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine monohydrochloride 1000 mg daily
Study: 28947022
Drug: FF/UMEC 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC 125 mcg
Study: 25452139
Drug: FF/UMEC 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC 250 mcg
Study: 16669728
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 or 30 mg/day)
Study: 14733999
Drug: PSA between
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA between 1.0 and 2.99 ng/ml with f/t PSA ratio < or =20%; 249 biopsies indicated, 159 performed (acceptance 63.9%)
Study: 9642018
Drug: Semantically complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically complex verbs (e.g., run)
Study: 9642018
Drug: Semantically simpler
Normalized name: Simplera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically simpler verbs (e.g., go)
Study: 2379442
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of glucose daily with no phosphorus
Study: 2379442
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of glucose with 7.5 mmol of phosphate daily
Study: 2379442
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g of glucose with 15 mmol of phosphate daily
Study: 373776
Drug: Euphyllin retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 700 mg/d
Study: 373776
Drug: Euphyllin retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 350 mg/d
Study: 29566588
Drug: ReSET (Strategic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReSET (Strategic Executive Treatment)
Study: 31157708
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic gel
Study: 28494914
Drug: 1mg oral
Normalized name: AXITINIB 1MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg oral melatonin daily 1 hour before bedtime one day before surgery and for another 5 consecutive days postoperatively
Study: 26249300
Drug: Telemedicine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine (8 sessions of behavioral activation therapy)
Study: 26249300
Drug: Same-room treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-room treatment (8 sessions of behavioral activation therapy)
Study: 22540770
Drug: Ciclosporin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (4 mg/kg/day)
Study: 22540770
Drug: Prednisolone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.75 mg/kg/day)
Study: 21079147
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus oral S-1 (40 mg/m2 twice per day) on days 1 to 14
Study: 19738339
Drug: Artemether-Lumefantrine (Coartem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (Coartem 20 mg/120 mg)
Study: 10381993
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nalmefene
Study: 2828818
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg naloxone
Study: 7026254
Drug: Ciramadol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 20 mg
Study: 7026254
Drug: Ciramadol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 60 mg
Study: 25157543
Drug: Tailored dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored dietary supplements for twice-daily consumption
Study: 22121190
Drug: Lopinavir/ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (400 mg twice daily)
Study: 17418297
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of autologous endothelial progenitor cells (EPCs) plus conventional therapy
Study: 8737145
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of trovafloxacin
Study: 1524757
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 10 mg nifedipine after awakening
Study: 2862057
Drug: Propranolol 120
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120 mg b.d. for one week
Study: 31751607
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light exposure (30-min pulses daily for 6 weeks, peak λ = 469 nm)
Study: 31751607
Drug: Amber placebo
Normalized name: amber
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amber placebo light (30-min pulses daily for 6 weeks, peak λ = 578 nm)
Study: 19515553
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m(2) IV q 4 weeks
Study: 19515553
Drug: Topotecan (TOPO)
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (TOPO) 1.5 mg/m(2) IV d1-5 q 3 weeks
Study: 11555521
Drug: Adenosine pretreatment
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine pretreatment (7‐min infusion of adenosine, total 650 microg/kg)
Study: 9777976
Drug: becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: becaplermin gel
Study: 31665507
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and education plus cervico‐mandibular manual therapy
Study: 16847681
Drug: Triazolam 0.1
Normalized name: triazolam 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.1 mg/70 kg
Study: 16847681
Drug: Triazolam 0.2
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.2 mg/70 kg
Study: 8853263
Drug: Bismuth triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth triple therapy
Study: 8853263
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor triple therapy
Study: 28858387
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day plus atorvastatin 40 mg/day
Study: 27294589
Drug: Travoprost administered
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost administered once daily to both eyes
Study: 27294589
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium hydrate administered twice daily to one eye
Study: 27294589
Drug: Flavin adenine
Normalized name: Flavin adenine dinucleotide
DrugBank: Flavin adenine dinucleotide (DB03147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavin adenine dinucleotide sodium administered twice daily to the other eye
Study: 25240971
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg zinc/day for 8 weeks)
Study: 20925938
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vildagliptin once daily
Study: 18567436
Drug: Artequick (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artequick (3.2 mg/Kg/day of artemisinin, 16 mg/Kg/day of piperaquine, and 0.16 mg/Kg/day of primaquine)
Study: 18567436
Drug: artesunate-mefloquine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: artesunate-mefloquine (4 mg/Kg/day of artesunate, 8 mg/Kg/day of mefloquine)
Study: 15838471
Drug: Patch angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch angioplasty with polyester urethane (Vascular‐patch, B. Braun Medical AG)
Study: 2126739
Drug: High-dose Estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Estramustine phosphate orally
Study: 26808136
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin
Study: 19489707
Drug: Individualized acupuncture
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized acupuncture points according to Traditional Chinese Medicine
Study: 16861717
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and surgical coronary disease treatments
Study: 16861717
Drug: Increased treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased treatment levels to reach 80% of eligible patients
Study: 2845564
Drug: Diethylcarbamazine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (30 mg/kg/d) for one week
Study: 573564
Drug: Domperidone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (5 or 10 mg)
Study: 28719527
Drug: Pupillometry-guided remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pupillometry-guided remifentanil administration
Study: 23062232
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus oxaliplatin (CapeOX) - capecitabine 1000 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Study: 19548076
Drug: L-propionyl-carnitine (LPC)
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionyl-carnitine (LPC) 1.2 g/day + PGE-1 60 mg/day
Study: 17447874
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (physical activity first, then fat intake 3 months later)
Study: 17447874
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (fat intake first, then physical activity 3 months later)
Study: 12699520
Drug: 10 micro
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro g of sufentanil + 500 micro g of adenosine
Study: 12699520
Drug: 10 micro
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro g of sufentanil
Study: 10895027
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (5 mg), repeated if necessary
Study: 10895027
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate
Study: 8826608
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral etoposide alone for 21 days (arm A)
Study: 8826608
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral etoposide for 21 days with GM‐CSF, 250 micrograms/m2, s.c. twice daily for the first 10 days of etoposide administration (arm B)
Study: 8826608
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral etoposide for 21 days with GM‐CSF twice daily for the sixth through second days preceding etoposide administration (arm C)
Study: 1360464
Drug: Cilest (ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilest (ethinyl estradiol 35 micrograms and norgestimate 250 mg) for 21 days, followed by 1-4 days of missed pills depending on the group.
Study: 1360464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no missed pills)
Study: 26053726
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (for patients with negative scans)
Study: 23580456
Drug: 70 ml
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 ml nitrate‐rich concentrated beetroot juice (BR)
Study: 21135862
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (Ph)
Study: 21135862
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment (Os)
Study: 17373905
Drug: PANVAC™ cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: PANVAC™ cancer vaccine therapy delivered through recombinant vaccinia and recombinant fowlpox vectors, injected subcutaneously.
Study: 17373905
Drug: PANVAC™ in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PANVAC™ in combination with conventional chemotherapy and/or radiation.
Study: 1598096
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin
Study: 12160204
Drug: Oral tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tobramycin and metronidazole for three days prior to surgery
Study: 12160204
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic cefmetazole every 3 hours during surgery
Study: 12160204
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic cefmetazole every 3 hours during surgery and luminal preparation of tobramycin during surgery
Study: 31574170
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L polyethylene glycol plus ascorbic acid
Study: 31421096
Drug: Bilateral Hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Hybrid Therapy (BHT)
Study: 31421096
Drug: Robot-assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted Therapy (RT)
Study: 31421096
Drug: Unilateral Hybrid
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral Hybrid Therapy (UHT)
Study: 26133561
Drug: TAC spray
Normalized name: triamcinolone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC spray with no rubbing
Study: 26133561
Drug: TAC spray
Normalized name: triamcinolone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC spray with rubbing
Study: 20166436
Drug: Promethazine hydrochloride
Normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promethazine hydrochloride determination method using LC-MS in human plasma (0.5 ml)
Study: 20166436
Drug: Promethazine hydrochloride
Normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promethazine hydrochloride determination method using LC-MS in human urine (0.1 ml)
Study: 16723363
Drug: Syndromic STI
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndromic STI packages (containing antibiotics, condoms, partner notification cards, and written information)
Study: 11416871
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (INO) weaning from 40 ppm
Study: 11416871
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of INO
Study: 11416871
Drug: INO weaning
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INO weaning with surfactant therapy
Study: 11416871
Drug: INO weaning
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INO weaning with specific dose reduction
Study: 29957756
Drug: Continue metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue metformin during peri-angiography (M (+) group)
Study: 29957756
Drug: Stop metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop metformin 24 hours prior to procedure (M (−) group)
Study: 26202461
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioural therapy (TF-CBT)
Study: 16863724
Drug: Buckwheat honey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buckwheat honey (50 g carbohydrate)
Study: 16863724
Drug: Cotton honey
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton honey (50 g carbohydrate)
Study: 31714309
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intravenous co‐amoxiclav
Study: 21738025
Drug: Zonisamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (50 mg/d, titrated up to 200 mg/d)
Study: 21738025
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 mg/d, titrated up to 100 mg/d)